Reported Earlier, Teva's AUSTEDO XR Receives FDA Green Light, One Pill, Once-Daily Dosage Now Available For TD And HD Chorea
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved Teva's AUSTEDO XR, a once-daily pill for treating tardive dyskinesia (TD) and Huntington's disease (HD) chorea. This new formulation offers more flexibility and effective symptom control, with improvements seen as early as two weeks for TD patients and significant reductions in Total Maximal Chorea (TMC) scores for HD patients.
May 30, 2024 | 7:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva's AUSTEDO XR has received FDA approval, providing a new once-daily treatment option for TD and HD chorea. This approval is likely to boost Teva's market position and revenue in the short term.
The FDA approval of AUSTEDO XR is a significant milestone for Teva, as it provides a new, flexible, and effective treatment option for TD and HD chorea. This is likely to enhance Teva's market position and drive revenue growth in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100